Last reviewed · How we verify
Enbrel liquid
Enbrel is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving autoimmune and inflammatory diseases.
Enbrel is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Enbrel liquid |
|---|---|
| Sponsor | Amgen |
| Drug class | TNF inhibitor (TNF receptor fusion protein) |
| Target | TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Enbrel (etanercept) is a soluble TNF receptor p75-Fc fusion protein that acts as a TNF inhibitor by binding circulating TNF-alpha and TNF-beta, preventing their interaction with cell surface TNF receptors. This blocks the inflammatory cascade mediated by TNF, reducing systemic inflammation and immune activation in autoimmune conditions. The liquid formulation provides an alternative to the lyophilized powder for subcutaneous injection.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Polyarticular juvenile idiopathic arthritis
- Plaque psoriasis
- Crohn's disease
Common side effects
- Injection site reactions (erythema, itching, pain)
- Upper respiratory tract infections
- Headache
- Dizziness
- Serious infections (including tuberculosis)
- Autoimmune phenomena (anti-dsDNA antibodies)
Key clinical trials
- Safety and Efficacy Study of Prefilled Liquid Etanercept(Yisaipu) for Active Ankylosing Spondylitis (PHASE3)
- Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept (PHASE3)
- Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function (PHASE2)
- Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers (PHASE1)
- Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection (PHASE1)
- Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects (PHASE1)
- Treatment for Subjects With Active Rheumatoid Arthritis (RA) (PHASE3)
- Enbrel Liquid Immunogenicity Protocol (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |